EGFR and lung carcinoma: MDM2 amplification is also associated with TKI resistance, particularly in lung cancer, where its inhibition has been explored as a means to overcome resistance to epidermal growth factor receptor (EGFR)-targeted therapies and BCR-ABL1 inhibitors in chronic myeloid leukemia (Carter et al., 2020; Dworakowska et al., 2004; Sun et al., 2020).